EGFR is not amplified in ameloblastoma

Publication date: Available online 6 March 2018
Source:Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Author(s): Victor Costa, Eduardo Rodrigues Fregnani, Felipe Paiva da Fonseca, Fábio de Abreu Alves, Clóvis Antônio Lopes Pinto, Estela Kaminagakura
Objective.The aim of this study was to investigate alterations in the EGFR gene and its protein expression for a better understanding of the biological behavior of ameloblastoma.Study design.Twenty-five samples of ameloblastoma were selected and the dual color fluorescence in situ hybridization (FISH) assay was performed. The results of FISH and immunohistochemistry reaction for EGFR and Ki67 were associated with the clinicopathological features and recurrence.Results.All analyzed cases presented disomy without any gene polysomy or amplification. Regarding to EGFR immunoexpression, 3 (12%) cases were considered negative and 22 (88%) were positive, of which 13 (52%) were weak and 9 (36%) were strong. All samples presented low positivity for Ki67. There is no association between EGFR expression and the clinicopathological features or recurrence (p > 0.05). In some cases, EGFR immunoexpression is observed without gene amplification.Conclusion.Ameloblastoma development, progression or recurrence seems not to be related with EGFR amplification or polysomy.



http://ift.tt/2H9K48h